From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Topics>
  3. Hepatitis

Hepatitis

The latest information on cirrhosis, interferon, ribavirin, vaccines, and more, drawn from across our primary care and specialty care areas. Sign up now for monthly e-mail alerts on new content.

SUMMARY AND COMMENT

α-Fetoprotein Screening in Patients with Hepatitis C

Positive predictive value for hepatocellular cancer was low; AFP screening is not recommended.

SUMMARY AND COMMENT

Transmission of Blood-Borne Pathogens in Injection-Drug Users

Hepatitis B virus and HIV are coming under control because of harm-reduction programs, but hepatitis C virus continues to be a problem.

SUMMARY AND COMMENT

Support for a 6-Month Surveillance Interval for Hepatocellular Carcinoma

In patients with cirrhosis, a 6-month interval detected as many cancers as a 3-month interval.

SUMMARY AND COMMENT

Acute Kidney Injury Predicts Mortality in Acute Alcoholic Hepatitis

New criteria for renal failure are superior to traditional criteria in predicting 90-day mortality and should be put to use in clinical settings.

SUMMARY AND COMMENT

Serum Ferritin Level Predicts Histologic Severity of NAFLD

Elevated serum ferritin was associated with a twofold increased risk for advanced disease among patients with NAFLD.

SUMMARY AND COMMENT

Elevated IgG4 in PSC Might Indicate More-Severe Disease

Serum immunoglobulin G4 levels >104 mg/dL were found in 22% of patients and were associated with higher Mayo risk scores.

SUMMARY AND COMMENT

Highlights from the Conference on Chronic Viral Hepatitis InfectionFree

Medical models that improve screening and effectiveness of treatment in the community setting are required to reduce the disease burden.

SUMMARY AND COMMENT

New Antivirals Show Promise for an Interferon-Free Hepatitis C Treatment

Patients with HCV genotype 1 and previous null response achieved a 36% sustained virologic response at 24 weeks of therapy with daclatasvir and asunaprevir alone.

SUMMARY AND COMMENT

Transplant-Associated HCV Transmission

Stricter guidelines or more-careful adherence to current ones might have prevented hepatitis C virus transmission to kidney and cardiopulmonary-patch recipients.

New HCV Treatments Look Promising for HIV/HCV-Coinfected Patients

Initial efficacy data for boceprevir and telaprevir are favorable, but other options under investigation may prove to be even better.

Read more Hepatitis articles >>

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

Browse arrow

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Copyright © 2012. Massachusetts Medical Society. All rights reserved.